Newsfeeds Archive - Page 2 of 3

4 minute read

Why Y-mAbs Therapeutics Shares Are Trading Higher By 50%? Here Are Other Stocks Moving In Friday’s Mid-Day Session

March 31, 12:47 PM

Gainers Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) climbed 49.9% to $4.93 after the company posted a profit for the fourth quarter.

ADN

1 minute read

Movers

12 Health Care Stocks Moving In Friday’s Pre-Market Session

By Benzinga Insights

March 31, 9:06 AM

Gainers G Medical Innovations (NASDAQ:GMVD) shares rose 45.2% to $2.41 during Friday’s pre-market session. The market value of…

BNOX

2 minute read

$1.6M Bet On ATAI Life Sciences? Check Out These 4 Penny Stocks Insiders Are Buying

By Lisa Levin

March 30, 7:15 AM

The Dow Jones closed higher by more than 300 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

ATAI

1 minute read

HC Wainwright & Co. Maintains Buy on Paratek Pharmaceuticals, Lowers Price Target to $10

By Benzinga Newsdesk

March 20, 7:06 AM

HC Wainwright & Co. analyst Ed Arce maintains Paratek Pharmaceuticals (NASDAQ:PRTK) with a Buy and lowers the price target from $20 to $10.

PRTK

1 minute read

Why Paratek Pharmaceuticals Stock Is Plunging Today

By Vandana Singh

March 16, 1:11 PM

Paratek Pharmaceuticals Inc’s (NASDAQ:PRTK) Q4 total revenue o reached $75.6 million compared to $31.8 million a year, beating the consensus of…

PRTK

1 minute read

Paratek Pharmaceuticals Announced Inclusion of NUZYRA® (omadacycline) in China’s National Reimbursement Drug List

By Charles Gross

January 18, 8:04 AM

Paratek Pharmaceuticals, Inc.

PRTK

2 minute read

Paratek Pharmaceuticals Announces Top Line Data From Pilot Efficacy Study For The Treatment Of Pulmonary Anthrax And Acceptance Of The Second Procurement Of NUZYRA Under BARDA Project BioShield

By Benzinga Newsdesk

December 19, 8:37 AM

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) today announced positive top line data from a pilot rabbit efficacy study evaluating NUZYRA’s effectiveness in the treatment of pulmonary anthrax. In the study, a 100%

PRTK